drugset / Trial / NCT00014690

ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00014690 ↗

Phase 2 Completed AstraZeneca
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of ZD9331 with or without topotecan in treating patients who have refractory or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

Timeline

Start
2001-03
Primary completion
—
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule — Intravenous
Subject plevitrexed Small molecule — Intravenous